Form 8-K - Current report:
SEC Accession No. 0001213900-25-064446
Filing Date
2025-07-16
Accepted
2025-07-16 06:29:09
Documents
13
Period of Report
2025-07-15
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0249160-8k_apimeds.htm   iXBRL 8-K 26453
2 PRESS RELEASE DATED JULY 15, 2025 ea024916001ex99-1_apimeds.htm EX-99.1 12075
  Complete submission text file 0001213900-25-064446.txt   208288

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE apus-20250715.xsd EX-101.SCH 3017
4 XBRL LABEL FILE apus-20250715_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE apus-20250715_pre.xml EX-101.PRE 22360
15 EXTRACTED XBRL INSTANCE DOCUMENT ea0249160-8k_apimeds_htm.xml XML 3688
Mailing Address 2 EAST BROAD STREET 2ND FLOOR HOPEWELL NJ 08525
Business Address 2 EAST BROAD STREET 2ND FLOOR HOPEWELL NJ 08525 848-201-5010
Apimeds Pharmaceuticals US, Inc. (Filer) CIK: 0001894525 (see all company filings)

EIN.: 851099700 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42545 | Film No.: 251126123
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)